Expert Interview
Diving into the topline results from the Phase 1b/2a SPOTLIGHT clinical trial of Briquilimab in patients with chronic inducible urticaria.
Ticker(s): JSPRInstitution: University of Pennsylvania/CHOP
- Allergy & Immunology specialist at the Children's Hospital of Philadelphia.
- Manages 400 patients a year for anaphylactic shock.
- Research interest in environmental and food allergies, Immunodeficiency in Cornelia de Lange syndrome and other genetic syndromes.
1. What is your background in treating chronic inducible urticaria, and what are the available treatment strategies, including the effectiveness of off-label XOLAIR?
Added By: slingshot_insights2. What are your thoughts on targeting c-KIT for mast cell depletion in urticaria, and how do you evaluate the use of provocation tests in the SPOTLIGHT trial?
Added By: slingshot_insights3. How do you interpret the response rates and timelines for efficacy in the SPOTLIGHT trial, particularly with single-dose treatments?
Added By: slingshot_insights4. What is your assessment of the safety profile of briquilimab, including side effects like neutropenia and its implications for repeat dosing?
Added By: slingshot_insights5. How do you compare briquilimab to barzolvolimab in terms of efficacy, safety, and convenience, and what factors might influence their market success?
Added By: slingshot_insightsAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
